The 21-gene Recurrence Score (Oncotype DX) assay has transformed risk stratification in hormone-receptor-positive (HR+), HER2-negative early-stage breast cancer, predicting distant recurrence risk and chemotherapy benefit [8,9,10]. The gene discussed is NR4A1; the disease is breast cancer.